Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 19/20 | 0.66 |
| ▸ | KDR | P35968 | 12/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17175155 | 0.83 | FGFR3 (0.56) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17175551 | 0.82 | FGFR3 (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17175552 | 0.80 | FGFR3 (0.60) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL29870618 | 0.79 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178236 | 0.79 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17035980 | 0.75 | FGFR3 (0.63) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL14905404 | 0.73 | FGFR3 (0.61) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17169977 | 0.73 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178551 | 0.72 | FGFR3 (0.83) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17036000 | 0.72 | FGFR3 (0.73) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855480-B1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-06-26 | — | — | EP | disclosed |
| US-10272087-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170000796-A1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-9447098-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 24/4885FGFR1 1/4885 |
| US-10272087-B2 | Pteridines as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 21/4885FGFR1 1/4885 |
| US-20170000796-A1 | PTERIDINES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 24/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.